Capstone Therapeutics (CAPS) Expected to Announce Earnings on Tuesday

Capstone Therapeutics (NASDAQ:CAPS) is projected to issue its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $12.5130 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Capstone Therapeutics Stock Performance

Shares of Capstone Therapeutics stock traded down $0.00 during trading on Wednesday, hitting $0.70. 26,613 shares of the company’s stock were exchanged, compared to its average volume of 228,095. The stock has a market capitalization of $6.40 million, a price-to-earnings ratio of -0.69 and a beta of -1.23. The business has a 50-day simple moving average of $0.64 and a 200-day simple moving average of $0.87. Capstone Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.29. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.35 and a current ratio of 0.95.

Hedge Funds Weigh In On Capstone Therapeutics

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC bought a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned approximately 1.51% of Capstone Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 2.55% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capstone Therapeutics in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.